Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review.
作者信息
Tajika Aran, Furukawa Toshi A, Shinohara Kiyomi, Kikuchi Shino, Toyomoto Rie, Furukawa Yuki, Ito Masami, Yoshida Kazufumi, Honda Yukiko, Takayama Tomohiro, Schneider-Thoma Johannes, Leucht Stefan
机构信息
Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Kyoto, Japan
Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Kyoto, Japan.
出版信息
BMJ Ment Health. 2023 Feb;26(1). doi: 10.1136/bmjment-2023-300654.
Abstract
摘要
相似文献
1
Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review.精神分裂症急性治疗抗精神病药物试验中的盲法成功率：一项系统评价
BMJ Ment Health. 2023 Feb;26(1). doi: 10.1136/bmjment-2023-300654.
2
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.氟哌啶醇与第一代抗精神病药物治疗精神分裂症及其他精神障碍的比较
Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2.
3
Antipsychotic combinations for schizophrenia.用于精神分裂症的抗精神病药物联合治疗
Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD009005. doi: 10.1002/14651858.CD009005.pub2.
4
Maintenance treatment with antipsychotic drugs for schizophrenia.使用抗精神病药物对精神分裂症进行维持治疗。
Cochrane Database Syst Rev. 2012 May 16(5):CD008016. doi: 10.1002/14651858.CD008016.pub2.
5
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.用于治疗精神分裂症的氟哌啶醇与低效价第一代抗精神病药物的对比
Cochrane Database Syst Rev. 2014 Jul 9;2014(7):CD009268. doi: 10.1002/14651858.CD009268.pub2.
6
Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia.对难治性精神分裂症患者换用抗精神病药物与继续当前治疗的比较
Cochrane Database Syst Rev. 2025 Apr 11;4(4):CD011885. doi: 10.1002/14651858.CD011885.pub2.
7
Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.三氟拉嗪与低效价第一代抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2014 Jul 8;2014(7):CD009396. doi: 10.1002/14651858.CD009396.pub2.
8
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.氯氮平联合不同抗精神病药物治疗难治性精神分裂症。
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD006324. doi: 10.1002/14651858.CD006324.pub3.
9
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.氟奋乃静与低效价第一代抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2014 Aug 3;2014(8):CD009230. doi: 10.1002/14651858.CD009230.pub2.
10
Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.奋乃静与低效第一代抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2014 Oct 7;2014(10):CD009369. doi: 10.1002/14651858.CD009369.pub2.
引用本文的文献
1
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.MM120（麦角酰二乙胺）单药治疗广泛性焦虑症：一项随机临床试验。
JAMA. 2025 Sep 4. doi: 10.1001/jama.2025.13481.
2
SAS macro programme for Bang's Blinding Index to assess and visualise the success of blinding in randomised controlled trials.用于班氏盲法指数的SAS宏程序，以评估和可视化随机对照试验中设盲的成功情况。
Gen Psychiatr. 2024 Dec 7;37(6):e101578. doi: 10.1136/gpsych-2024-101578. eCollection 2024.
3
Are the results of open randomised controlled trials comparing antipsychotic drugs in schizophrenia biased? Exploratory meta- and subgroup analysis.比较抗精神病药物治疗精神分裂症的开放性随机对照试验结果是否存在偏差？探索性Meta分析和亚组分析。
Schizophrenia (Heidelb). 2024 Feb 15;10(1):17. doi: 10.1038/s41537-024-00442-8.
本文引用的文献
1
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis.精神分裂症亚组患者对不同抗精神病药物的反应：系统评价和荟萃分析。
Lancet Psychiatry. 2022 Nov;9(11):884-893. doi: 10.1016/S2215-0366(22)00304-2. Epub 2022 Oct 10.
2
Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010.2000-2010 年精神分裂症和情感障碍随机对照试验中盲法评估的系统评价。
Psychother Psychosom. 2013;82(3):152-60. doi: 10.1159/000346144. Epub 2013 Mar 21.
3
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.单剂量20毫克的二氢麦角隐亭（DAR - 0100），一种完全的多巴胺D1激动剂，在精神分裂症患者中是安全且耐受性良好的。
Schizophr Res. 2007 Jul;93(1-3):42-50. doi: 10.1016/j.schres.2007.03.011. Epub 2007 Apr 30.
4
Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.接受检验的盲法试验：对报告盲法成功检验的随机临床试验的分析
Int J Epidemiol. 2007 Jun;36(3):654-63. doi: 10.1093/ije/dym020. Epub 2007 Apr 17.
5
Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials.视而不见：随机、安慰剂对照试验随机样本中报告的盲法实施成功率
BMJ. 2004 Feb 21;328(7437):432. doi: 10.1136/bmj.37952.631667.EE. Epub 2004 Jan 22.
6
A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics.氯丙嗪研究：针对慢性半精神错乱型精神分裂症患者的方法与结果
J Nerv Ment Dis. 1955 Oct;122(4):301-14.
7
A controlled study of haloperidol in chronic schizophrenia.氟哌啶醇治疗慢性精神分裂症的对照研究。
Curr Ther Res Clin Exp. 1967 Aug;9(8):407-12.
8
Physician bias and the double-blind.医生偏见与双盲法。
Arch Gen Psychiatry. 1969 Mar;20(3):315-20. doi: 10.1001/archpsyc.1969.01740150059009.
Zotero 插件